Establishment Labs Holdings Showcases Mia Femtech™ Clinical Success at Global Symposium

Establishment Labs Unveils Promising Mia Femtech™ Clinical Results at Global Symposium

Establishment Labs Holdings Inc., a prominent player in the medical technology sector, focuses on enhancing women's health through innovative solutions in breast aesthetics and reconstruction. Recently, the company presented impressive three-year clinical results for its Mia Femtech™ product at the 9th Annual World Symposium on Ergonomic Implants (WSEI) in Barcelona, Spain. This prospective study, known as the Mia Femtech Clinical Study, was approved by an Institutional Review Board (IRB) and enrolled 100 subjects between December 2020 and April 2021. The results reveal a striking 0.0% rate of complications related to capsular contracture (Baker Grade III/IV) or ruptures, underscoring the product's safety and efficacy over the three-year follow-up period.

The study also reports no instances of infection, hematoma, or seroma requiring medical intervention, and maintains a 93% follow-up compliance rate. Notably, there are no adverse changes in nipple or breast sensation observed among participants. The only complications noted were a 1.0% occurrence rate of malposition/displacement and a reoperation rate that is equally low. CEO Juan José Chacón-Quirós emphasizes the significance of these findings, asserting that they are among the best reported in breast implant studies at the three-year mark. He suggests that the results reinforce the notion that minimally invasive procedures represent the future of breast aesthetics, aligning with the growing demand for safer and more effective solutions in the industry.

The timing of these results is particularly advantageous for Establishment Labs, as the recent FDA approval of Motiva implants has created a surge in demand for their innovative technologies. The company is poised to introduce the Mia Femtech™ product to the U.S. market, leveraging this momentum to enhance its presence in existing markets. The symposium, which gathers over 500 professionals, including leading plastic surgeons and researchers, serves as an ideal platform for Establishment Labs to showcase its advancements in breast tissue preservation and engage with industry experts about its expanding portfolio of technologies.

In addition to sharing clinical results, the WSEI symposium provides a vital opportunity for knowledge exchange on innovations in breast aesthetics. This gathering not only highlights the growing interest in reliable and effective breast implant options but also positions Establishment Labs as a leader in the field. As the company continues to push the boundaries of medical technology and women's health, its commitment to safety and excellence remains at the forefront of its mission.